Besifloxacin
Besivance (besifloxacin) is a small molecule pharmaceutical. Besifloxacin was first approved as Besivance on 2009-05-28. It is used to treat bacterial conjunctivitis, bacterial infections, and protozoan infections in the USA.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| infections | D007239 |
| eye diseases | D005128 |
Trade Name
FDA
EMA
Besivance
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Besifloxacin hydrochloride
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| BESIVANCE | Bausch Health Companies | N-022308 RX | 2009-05-28 | 1 products, RLD, RS |
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| besivance | New Drug Application | 2024-07-03 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| bacterial infections | — | D001424 | A49 |
| bacterial conjunctivitis | EFO_1000829 | D003234 | H10.0 |
| protozoan infections | — | D011528 | B50-B64 |
Agency Specific
FDA
EMA
No data
HCPCS
No data
Clinical
Clinical Trials
22 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Cataract | D002386 | EFO_0001059 | H26.9 | 1 | — | — | 4 | — | 5 |
| Cataract extraction | D002387 | — | — | 1 | — | — | 3 | — | 4 |
| Pseudophakia | D019591 | — | — | — | — | — | 1 | — | 1 |
| Corneal diseases | D003316 | — | H18.9 | — | — | — | 1 | — | 1 |
| Blepharitis | D001762 | EFO_0009536 | H01.0 | — | — | — | 1 | — | 1 |
| Penetrating eye injuries | D015807 | EFO_1001323 | S05.6 | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Bacterial conjunctivitis | D003234 | EFO_1000829 | H10.0 | 1 | 2 | 6 | — | — | 8 |
| Conjunctivitis | D003231 | — | H10 | 1 | 2 | 5 | — | — | 7 |
| Communicable diseases | D003141 | — | — | — | 1 | 1 | — | — | 2 |
| Keratitis | D007634 | — | H16 | — | — | 1 | — | 1 | 2 |
| Bacterial eye infections | D015818 | — | — | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Infections | D007239 | EFO_0000544 | — | — | 1 | — | — | — | 1 |
| Corneal ulcer | D003320 | — | H16.0 | — | 1 | — | — | — | 1 |
| Ulcer | D014456 | MPATH_579 | — | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 2 | — | — | — | — | 2 |
| Lacrimal duct obstruction | D007767 | — | — | 1 | — | — | — | — | 1 |
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Besifloxacin |
| INN | besifloxacin |
| Description | Besifloxacin is a member of quinolines. |
| Classification | Small molecule |
| Drug class | antibacterials (quinolone derivatives) |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | N[C@@H]1CCCCN(c2c(F)cc3c(=O)c(C(=O)O)cn(C4CC4)c3c2Cl)C1 |
Identifiers
| PDB | — |
| CAS-ID | 141388-76-3 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1201760 |
| ChEBI ID | — |
| PubChem CID | 10178705 |
| DrugBank | — |
| UNII ID | BFE2NBZ7NX (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
No data
Estimated US medical usage
Besifloxacin
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 477 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
433 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use